XEVUDY

This brand name is authorized in Estonia, Ireland, Japan, Poland, Romania, United Kingdom

Active ingredients

The drug XEVUDY contains one active pharmaceutical ingredient (API):

1 Sotrovimab
UNII 1MTK0BPN8V - SOTROVIMAB

Sotrovimab is a dual action, engineered human IgG1 mAb that binds to a conserved epitope on the spike protein receptor binding domain of SARS-CoV-2. It is used for the treatment of symptomatic adults and adolescents with acute covid-19 infection who do not require oxygen supplementation and who are at increased risk of progressing to severe covid infection.

Read about Sotrovimab

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
XEVUDY Concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
J06BD Antiviral monoclonal antibodies J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins
Discover more medicines within J06BD

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1872817
Country: JP 医薬品医療機器総合機構 Identifier(s): 62504A4A1023
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100463322
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W68344001

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.